Revivent TC (coronary heart disease treatment device)

2023: Device Announcement

In mid-April 2023, the American company BioVentrix announced the creation of a Revivent TC device designed to treat coronary heart disease. To implement the project, the startup raised $48.5 million in venture capital financing. The funds should help the startup bring the development to registration by the Food and Drug Administration (FDA) and bring it to the US market. The round was led by Andera Partners, backed by Cormorant Asset Management, Taglich Brothers, Squarepoint Capital and Richmond Brothers.

Heart failure for 2023 has become an epidemic. Every year around the world, the number of people suffering from this disease is growing. Heart failure develops as a complication of various diseases of the cardiovascular system. Treating patients with advanced heart failure by restoring the left ventricle is recognized by the clinical cardiology community as the most relevant approach, BioVentrix President and CEO Jim Dillon stated.

Revivent TC (coronary heart disease treatment device)

The minimally invasive Revivent TC system, formerly the winner of the Fierce Medtech Fierce 15, is designed to repair the shape of the left ventricle of the heart after a severe injury caused by a heart attack. By implanting a number of small anchors into the dilated and scar wall of the heart, the muscle can be tightened to help it pump blood more efficiently into the body, the developers said. Revivent TC allows for reduced left ventricular volume and radius by excluding scar in patients with systolic heart failure.

BioVentrix's venture financing series is facilitating the company's filing for Revivent TC's full pre-market approval, slated for late 2023, as well as preparations for a commercial launch in the United States.^[1]

Notes